RecruitingInterventionalPhase 2Last updated Mar 3, 2026

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

A Phase II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

Overview

ClinicalTrials.gov ID: NCT07114315
Lead Sponsor: AkesoINDUSTRY
Brief Summary: This is an open-label, multi-center phase II clinical study consisting of two parts:

Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer.

Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Study Type

Status

Study Record Dates

NCT06938321Recruiting

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

NCT05951608Active, not recruiting

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

NCT05214482Completed

A Study of AK112 in Advanced Malignant Tumors

NCT07591090Recruiting

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

NCT06646055Active, not recruiting

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

NCT05689853Recruiting

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors